Rani Therapeutics Holdings, Inc. (RANI)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.62
- As of
Kresmion compiles this page from RANI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Rani Therapeutics Holdings, Inc. (RANI): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.
See the full RANI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RANI on one page. Preview it with sample data, then open it live with a free account.
Preview the RANI dossierActive events for RANI
- mediumEarnings above estimates
Q2-2026: Beat consensus by 21.6%, EPS $-0.04 vs $-0.051 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +4267% to RANI (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +1629% to RANI (2026Q2)
- mediumEarnings above estimates
Q2-2025: Beat consensus by 9.5% - EPS $-0.18 vs $-0.1989 estimate
- lowEarnings above estimates
Q1-2026: EPS $-0.04 vs $-0.0459 estimate, +0.01 on a near-zero consensus
FREE, NO ACCOUNT
Every event on RANI, as it fires
New filings, 13F moves and cross asset events on RANI land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RANI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 753018100 · 2026Q2 | $488K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 753018100 · 2026Q2 | $328K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RANI
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
RANI against its peers
RANI's operating margin of -2346.0% ranks in the 23rd percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | RANI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.6M USD | 3.3M USD | 38 | 11 |
| Gross margin | n/a | 66.9% | n/a | 7 |
| Operating margin | -2346.0% | -152.0% | 23 | 10 |
| Net margin | -1817.1% | -123.3% | 21 | 11 |
| Return on equity | -89.9% | -89.7% | 50 | 20 |
Peers (24): NMRA, PMN, NTRB, CRDF, MAIA, MNOV, CSBR, OKYO, CING, CGTX, ACRV, PDSB, EQ, CRBP, PTHS, SPRO, TENX, HYFT, AURX, MIST, FBIO, ONCY, RNXT, XBIT. Left out: TELO (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (RANI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RANI on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RANI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.